医药相关股逆市造好 药明生物/平安好医生/阿里健康/爱康/微创涨3%-8%
南韩及德国放宽禁闭措施後，新冠肺炎新增确诊个案回升，市场忧虑全球各国过早放宽禁闭措施重启经济活动或会出现第二波新冠肺炎疫情，加上中美贸易前景不明朗，道指期货续吐198点或0.8%报23,926。亚太区股市全面受压，尤其是恒指曾吐465点或1.9%低见24,136，现造24,223元，回吐378点或1.5%，星股及澳股也吐1%-1.3%。
不过，本港医药相关股普遍逆升，尤其是平安好医生(01833.HK)及阿里健康(00241.HK)高见114.3元及19.84元，现造114元及19.82元，续升4.3%及6%。
康希诺(06185.HK)曾升破上月尾所创上市高位168元，最高见176.3元，现造168元，续升3%。药明生物(02269.HK)更连续第三天创上市高位，最高见130.8元，现造130.3元，续升2.6%；旗下药明康德(02359.HK)高见114元，现造112.3元，续升1.4%。
无惧首季亏损扩至3.6亿美元的百济神州(06160.HK)升破百天线(93.84元)，最高见96.5元，现造96.25元，续升3.5%。君实生物(01877.HK)回升4.3%报38.7元，股价重越10天线(38.6元)。
威高股份(01066.HK)回升2.8%报12.3元；绿药制药(02186.HK)及联邦制药(03933.HK)高见4.03元7.32元，现造3.98元及7.25元，续升3.6%。三生制药(01530.HK)高见9.1元，现造8.97元，续升1.2%。
爱康医疗(01789.HK)及春立医疗(01858.HK)高见22.4元及44.35元，现造22.25元及43.9元，回升7%及3.8%，後者重越10天及20天线。启明医疗(02500.HK)升2.3%曾高见58.95元。微创医疗(00853.HK)回升8%报20.1元，仅次於3月16日所造上市高位20.4元。不过，两大蓝筹药股中生(01177.HK)及石药(01093.HK)随大市跌逾1%。
中国外交部昨天就「中国黑客试图窃取美国新冠肺炎疫苗成果」说法回应指，中国於新冠疫苗研究和治疗方法方面均走在世界前列。据之前曾披露消息，中国四种国产新冠疫苗研发正齐头并进，其中军事科学院军事医学研究院陈薇院士团队腺病毒载体重组疫苗，已於4月中进入二期临床试验，为全球首款进入II期试验的疫苗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
